Human Tissue and Genomics Core
Human Tissue and Genomics Core
批准号:
8890149
负责人:
Hans H. Herfarth
金额:
$29.04万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
已结题
起止时间:
至 2016-06-30
关键词:
AddressAnimal ExperimentationAnimal ModelAutomobile DrivingBioinformaticsBiologicalBiological AssayBiopsyCellsChromatinClinicalDNADataData AnalysesDatabasesDevelopmentDiagnosticDiseaseEnteralExcisionExperimental ModelsFamily memberFormaldehydeFreezingGene ExpressionGene Expression RegulationGene TargetingGenesGeneticGenomeGenomicsGoalsHigh-Throughput Nucleotide SequencingHumanImmuneImmunophenotypingIndividualInflammatory Bowel DiseasesInflammatory ResponseInflammatory disease of the intestineInterleukin-10Interleukin-12IntestinesLinkMediatingMicrobeModelingMolecularMusOperative Surgical ProceduresPathogenesisPatientsPatternPeripheral Blood Mononuclear CellPhenotypePlayPopulationProcessProteinsRNARegulator GenesRegulatory ElementResearch InfrastructureResearch PersonnelResourcesRoleSamplingScienceSerumSingle Nucleotide PolymorphismTechnical ExpertiseTestingTherapeuticTissue BankingTissue BanksTissuesUnited States National Institutes of HealthVariantbasechromatin immunoprecipitationclinical phenotypecomputerized data processingcostdeep sequencingdisease phenotypedisorder controlfunctional genomicsgenome wide association studyhigh throughput screeninghuman diseasehuman tissueinnovationinterestmeetingsmicroorganism interactionnew technologyprogramstooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The primary goal of Core B is to provide individual projects with intestinal tissue, isolated cell populations, and
functional genomic information from clinically characterized IBD patients and healthy controls. This core will
overcome a widely acknowledged roadblock in the use of animal models - direcfing animal research to address
questions that will be directly translatable to human IBD. The data and tissue banks and novel technologies
developed through this core will allow investigators the opportunity to correlate molecular findings across
model species to human diseases. Core B will leverage substanfial existing resources and expertise at UNC.
There is an established infrastructure for obtaining and processing surgical resecfions and intestinal biopsies.
The "Tissue" component of Core B will process and provide frozen intestinal tissue; RNA and protein extracts
from intestinal tissue, deidentified clinical information on disease phenotype, and at the request of
invesfigators, isolated intestinal cell populations. Where required, the core will be able to provide matched
serum in peripheral blood mononuclear cell populafions as well as DNA to correlate immunophenotype, clinical
phenotype with genetic background. Understanding the molecular basis of human IBD is far from being
achieved. High throughput assays that permit the identification of gene regulatory networks in a heterogeneous
disease like IBD is of paramount importance to elucidate the pathogenic mechanisms of IBD and for the
development of diagnostic tools and of innovative therapeutics. The "Genomics" component of Core B will use
complementary high throughput assays of chromatin status (FAIRE, and ChIP) and gene expression (RNA)
from isolated single cells (murine and human), and clinically phenotyped pafients combined with deep
sequencing. Each Project profits by centralized data processing and analysis that increases feasibility and
efficiency, decreases costs for each Program Project investigator and limits variations that may occur from
technical error. Furthermore, Core B capitalizes and builds on the financial commitments and technical
expertise already made by the NIH (ENCODE, 1000 genomes, and HapMap projects) and the Carolina Center
for Genome Sciences. Data generated by Core B will allow each investigator to study active regulatory
elements in the genome at a level of detail yet to be performed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MEthotrexate Response in Treatment of UC - MERIT-UC
-
批准号:8703089
-
项目类别:
-
资助金额:$154.89万
-
财政年份:2011
-
负责人:Hans H. Herfarth
-
依托单位:
MEthotrexate Response in Treatment of UC - MERIT-UC
-
批准号:8499298
-
项目类别:
-
资助金额:$157.14万
-
财政年份:2011
-
负责人:Hans H. Herfarth
-
依托单位:
MEthotrexate Response in Treatment of UC - MERIT-UC
-
批准号:8916675
-
项目类别:
-
资助金额:$154.37万
-
财政年份:2011
-
负责人:Hans H. Herfarth
-
依托单位:
MEthotrexate Response in Treatment of UC - MERIT-UC
-
批准号:8316407
-
项目类别:
-
资助金额:$167.05万
-
财政年份:2011
-
负责人:Hans H. Herfarth
-
依托单位:
MEthotrexate Response in Treatment of UC - MERIT-UC
-
批准号:8163797
-
项目类别:
-
资助金额:$182.93万
-
财政年份:2011
-
负责人:Hans H. Herfarth
-
依托单位:
Methotrexate Response In Treatment of UC
-
批准号:7740248
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2009
-
负责人:Hans H. Herfarth
-
依托单位:
CLINICAL TRIAL: CIPROFLOXACIN FOR PROPHYLACTIC PREVENTION OF POSTOPERATIVE ENDOS
-
批准号:7716910
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2008
-
负责人:Hans H. Herfarth
-
依托单位:
Pilot study on the safety and efficacy of ciprofloxacin for prophylactic preventi
-
批准号:7357376
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2007
-
负责人:Hans H. Herfarth
-
依托单位:
Pilot study on the safety and efficacy of ciprofloxacin for prophylactic preventi
-
批准号:7500702
-
项目类别:
-
资助金额:$21.46万
-
财政年份:2007
-
负责人:Hans H. Herfarth
-
依托单位:
Human Tissue and Genomics Core
-
批准号:9091533
-
项目类别:
-
资助金额:$29.04万
-
财政年份:--
-
负责人:Hans H. Herfarth
-
依托单位:
Human Tissue and Genomics Core
-
批准号:8604569
-
项目类别:
-
资助金额:$25.4万
-
财政年份:--
-
负责人:Hans H. Herfarth
-
依托单位:
Human Tissue and Genomics Core
-
批准号:8737243
-
项目类别:
-
资助金额:$29.04万
-
财政年份:--
-
负责人:Hans H. Herfarth
-
依托单位:
海外基金